Alzamend Neuro Regains Nasdaq Listing Compliance With $5.8M Equity
Image
Atlanta – – September 18, 2026 -- Alzamend Neuro, Inc. (Nasdaq: ALZN) has regained compliance with Nasdaq's minimum stockholders' equity rule, ending a listing threat that began in March 2026.
Nasdaq confirms Alzamend's equity now exceeds required threshold
Nasdaq's Listing Qualifications Staff issued a notification letter dated September 14, 2026, confirming Alzamend satisfies Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2.5 million. Alzamend's Quarterly Report on Form 10-Q for the quarter ended July 31, 2026, filed with the SEC on September 10, 2026, showed stockholders' equity of $5,802,680, more than double the required minimum.